Wall Street Signals: Amarin Corporation plc (AMRN) Q1 2019 Earnings Call Transcript

Amarin Corporation plc (AMRN) Q1 2019 Earnings Call Transcript

Amarin Corporation plc  (NASDAQ: AMRN)
Q1 2019 Earnings Call
May. 01, 20197:30 a.m. ET


  • Prepared Remarks
  • Questions and Answers
  • Call Participants

Prepared Remarks:

Welcome to Amarin Corporation's conference call to discuss its Financial and Operating Results for the First Quarter of 2019. This conference call is being recorded today, May 1st, 2019.
I would like to turn the conference over to Elisabeth Schwartz, Senior Director of Investor Relations of Amarin. Please go ahead.
Elisabeth Schwartz -- Senior Director of Investor Relations and Corporate Communications
If it's not too much trouble know that this telephone call will contain forward-looking articulations that are proposed to be secured under the Safe Harbor given by the Private Securities Litigation Reform Act. Instances of such explanations incorporate, yet are not restricted to, our present assumptions about our business and money-related execution, including dimensions of Vascepa shipments and remedies, Vascepa item and permitting incomes, costs and other business measurements, net edge, consumptions and sufficiency of our monetary assets, our present desires for logical introductions, productions, administrative surveys and related planning thereof, our desires that REDUCE-IT results could prompt another treatment worldview in the patient populace contemplated, our arrangements and readiness for expanded advancement of Vascepa and related market situating and potential, our arrangements to buy extra supply of Vascepa and our objectives in regards to the planning and extent of global extension and our present designs for deals power and other business development.
These statements are based on information available to us today, May 1st, 2019. We may not actually achieve our goals, carry out our plans or intentions or meet the expectations disclosed in our forward-looking statements. Actual results or events could differ materially, so you should not place undue reliance on these statements. We assume no obligation to update these statements as circumstances change. Our forward-looking statements do not reflect the potential impact of significant transactions we may enter into such as mergers, acquisitions, dispositions, joint ventures or any material agreements that we may enter into, amend or terminate.
For additional information concerning the factors that could cause actual results to differ materially, please see the Forward-looking Statements section in today's press release and the Risk Factors section of our quarterly report on Form 10-Q for the quarter ended March 31st, 2019. These documents have been filed with the SEC and are available through the Investor Relations section of our website at amarincorp.com. We encourage everyone to read these documents.
This call is intended for investors in Amarin and is not intended to promote the use of Vascepa outside its approved indication. Please note that that we are also providing slides to accompany this morning's call. These slides, which can be found on our website at amarincorp.com, in the Investor Relations section, under the subcategory Events and Presentations, summarize some of the key updates discussed on today's call.
Finally, an archive of this call will be posted on the Amarin website, also in the Investor Relations section.
I'll now turn the call over to John Thero, President and Chief Executive Officer of Amarin.
John Thero -- President and Chief Executive Officer
Good morning, everyone. Thank you for joining us today. I look forward to discussing Amarin's progress and outlook with you. Q1 was a very good quarter for Amarin. We made important progress in numerous areas, and we are confident that we will continue to execute on the strategy, plan, and goals we described in our last investor conference call. Our aim is not to repeat all such matters in this call, but to focus on highlights in another update.
In this discussion, please note that despite the progress we made in Q1, we are still very early in the second of the four phases of commercialization that we described in our last investor conference call. In particular, we do not yet have an expanded label for Vascepa. As previously described, a broader label will facilitate broader product promotion. As listed in today's press release, Amarin's highlights from the first quarter of 2019 included a 67% increase in total net revenue, such revenue was $73.3 million in Q1 2019, compared to $43.9 million in the same period of last year.